Funk Julianne S, Klimovich Maria, Drangenstein Daniel, Pielhoop Ole, Hunold Pascal, Borowek Anna, Noeparast Maxim, Pavlakis Evangelos, Neumann Michelle, Balourdas Dimitrios-Ilias, Kochhan Katharina, Merle Nastasja, Bullwinkel Imke, Wanzel Michael, Elmshäuser Sabrina, Teply-Szymanski Julia, Nist Andrea, Procida Tara, Bartkuhn Marek, Humpert Katharina, Mernberger Marco, Savai Rajkumar, Soussi Thierry, Joerger Andreas C, Stiewe Thorsten
Institute of Molecular Oncology, Philipps-University, Marburg, Germany.
Institute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.
Nat Genet. 2025 Jan;57(1):140-153. doi: 10.1038/s41588-024-02039-4. Epub 2025 Jan 7.
The mutational landscape of TP53, a tumor suppressor mutated in about half of all cancers, includes over 2,000 known missense mutations. To fully leverage TP53 mutation status for personalized medicine, a thorough understanding of the functional diversity of these mutations is essential. We conducted a deep mutational scan using saturation genome editing with CRISPR-mediated homology-directed repair to engineer 9,225 TP53 variants in cancer cells. This high-resolution approach, covering 94.5% of all cancer-associated TP53 missense mutations, precisely mapped the impact of individual mutations on tumor cell fitness, surpassing previous deep mutational scan studies in distinguishing benign from pathogenic variants. Our results revealed even subtle loss-of-function phenotypes and identified promising mutants for pharmacological reactivation. Moreover, we uncovered the roles of splicing alterations and nonsense-mediated messenger RNA decay in mutation-driven TP53 dysfunction. These findings underscore the power of saturation genome editing in advancing clinical TP53 variant interpretation for genetic counseling and personalized cancer therapy.
TP53是一种肿瘤抑制基因,在大约一半的癌症中发生突变,其突变图谱包含超过2000种已知的错义突变。为了在个性化医疗中充分利用TP53突变状态,深入了解这些突变的功能多样性至关重要。我们使用CRISPR介导的同源定向修复进行饱和基因组编辑,在癌细胞中构建了9225种TP53变体,从而进行了深度突变扫描。这种高分辨率方法覆盖了所有癌症相关TP53错义突变的94.5%,精确地描绘了单个突变对肿瘤细胞适应性的影响,在区分良性和致病性变体方面超过了以往的深度突变扫描研究。我们的结果揭示了即使是细微的功能丧失表型,并确定了有前景的可进行药物重新激活的突变体。此外,我们还揭示了剪接改变和无义介导的信使RNA降解在突变驱动的TP53功能障碍中的作用。这些发现强调了饱和基因组编辑在推进临床TP53变体解释以进行遗传咨询和个性化癌症治疗方面的作用。